허가사항 범위 내에서 최대 4주기까지 인정하며, 인정주기를 초과하는 경우에는 약값 전액을 환자가 부담토록 함.
■ 고시 신설 고시번호(시행일자)
고시 제2025-169호(2025.10.1.)
■ 고시 신설 사유
○교과서, 가이드라인, 임상논문, 학회(전문가) 의견 등을 참조하여 급여 인정주기 명확화
■ 관련문헌 등
· Williams Obstetrics, 26e. 2022.
· 산과학 제6판. 2019.
· Women's Health Across the Lifespan. 3rd. 2024.
· WHO recommendation on Tocolytic therapy for improving preterm birth outcomes. 2022.
· Preterm labour and birth. NICE. 2022.
· Management of preterm labor: Clinical practice guideline and recommendation by the WAPM-World Association of Perinatal Medicine and the PMF-Perinatal Medicine Foundation. European Journal of Obstetrics and Gynecology 291. 2023. 196？205.
· Wilson A et al. Tocolytics for delaying preterm birth: a network meta-analysis. Cochrane Database of Systematic Rev. 2022 Aug 10;8(8):CD014978.
· Yang Yu et al. Effectiveness and safety of atosiban versus conventional treatment in the management of preterm labor. Taiwanese Journal of Obstetrics & Gynecology 59. 2020. 682-685.
· Ali et al. Systematic review and meta-analysis of randomized controlled trials of atosiban versus nifedipine for inhibition of preterm labor. Int J Gynaecol Obstet. 2019.
· TAJ Nijman et al. Cost effectiveness of nifedipine compared with atosiban in the treatment of threatened preterm birth (APOSTEL III trial). BJOG. 2019.
· Ronald F Lamont et al. Safety and Efficacy of Tocolytics for the Treatment of Spontaneous Preterm Labour. Curr Pharm Des. 2019;25(5):577-592.